vs
合众银行（FSBC）与RHYTHM PHARMACEUTICALS, INC.（RYTM）财务数据对比。点击上方公司名可切换其他公司
RHYTHM PHARMACEUTICALS, INC.的季度营收约是合众银行的1.3倍（$57.3M vs $45.1M），合众银行净利率更高（41.3% vs -83.0%，领先124.3%），过去两年RHYTHM PHARMACEUTICALS, INC.的营收复合增速更高（48.5% vs 21.3%）
合众银行是总部设在美国明尼阿波利斯、在特拉华州注册的美国跨国银行机构，截至2025年为美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的银行。它旗下核心运营实体为美国银行全国协会，以US Bank品牌开展业务，提供银行、投资、抵押等金融服务。
Rhythm Pharmaceuticals是一家专注于罕见病领域的生物制药企业，主要开发和商业化针对罕见遗传性肥胖症的靶向疗法，覆盖POMC缺陷、LEPR缺陷、巴德-毕德氏综合征等适应症，服务北美、欧洲地区缺少有效治疗方案的患者群体。
FSBC vs RYTM — 直观对比
营收规模更大
RYTM
是对方的1.3倍
$45.1M
净利率更高
FSBC
高出124.3%
-83.0%
两年增速更快
RYTM
近两年复合增速
21.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $57.3M |
| 净利润 | $18.6M | $-47.5M |
| 毛利率 | — | 91.6% |
| 营业利润率 | — | -82.2% |
| 净利率 | 41.3% | -83.0% |
| 营收同比 | — | 36.9% |
| 净利润同比 | 42.0% | -9.6% |
| 每股收益（稀释后） | $0.87 | $-0.73 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSBCRYTM
| Q1 26 | $45.1M | — | ||
| Q4 25 | $43.5M | $57.3M | ||
| Q3 25 | $41.3M | $51.3M | ||
| Q2 25 | $38.3M | $48.5M | ||
| Q1 25 | $35.3M | $32.7M | ||
| Q4 24 | $35.2M | $41.8M | ||
| Q3 24 | $31.8M | $33.3M | ||
| Q2 24 | $30.7M | $29.1M |
净利润FSBCRYTM
| Q1 26 | $18.6M | — | ||
| Q4 25 | $17.6M | $-47.5M | ||
| Q3 25 | $16.3M | $-52.9M | ||
| Q2 25 | $14.5M | $-46.6M | ||
| Q1 25 | $13.1M | $-49.5M | ||
| Q4 24 | $13.3M | $-43.3M | ||
| Q3 24 | $10.9M | $-43.6M | ||
| Q2 24 | $10.8M | $-32.3M |
毛利率FSBCRYTM
| Q1 26 | — | — | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
营业利润率FSBCRYTM
| Q1 26 | — | — | ||
| Q4 25 | 52.9% | -82.2% | ||
| Q3 25 | 53.8% | -102.6% | ||
| Q2 25 | 52.4% | -93.4% | ||
| Q1 25 | 52.0% | -143.7% | ||
| Q4 24 | 55.1% | -98.6% | ||
| Q3 24 | 48.0% | -132.0% | ||
| Q2 24 | 49.4% | -139.2% |
净利率FSBCRYTM
| Q1 26 | 41.3% | — | ||
| Q4 25 | 40.6% | -83.0% | ||
| Q3 25 | 39.6% | -103.1% | ||
| Q2 25 | 37.9% | -96.1% | ||
| Q1 25 | 37.1% | -151.4% | ||
| Q4 24 | 37.9% | -103.6% | ||
| Q3 24 | 34.4% | -131.2% | ||
| Q2 24 | 35.2% | -110.9% |
每股收益（稀释后）FSBCRYTM
| Q1 26 | $0.87 | — | ||
| Q4 25 | $0.83 | $-0.73 | ||
| Q3 25 | $0.77 | $-0.82 | ||
| Q2 25 | $0.68 | $-0.75 | ||
| Q1 25 | $0.62 | $-0.81 | ||
| Q4 24 | $0.61 | $-0.71 | ||
| Q3 24 | $0.52 | $-0.73 | ||
| Q2 24 | $0.51 | $-0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $644.4M | $388.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $458.5M | $139.1M |
| 总资产 | $5.0B | $480.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FSBCRYTM
| Q1 26 | $644.4M | — | ||
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $319.1M |
股东权益FSBCRYTM
| Q1 26 | $458.5M | — | ||
| Q4 25 | $445.8M | $139.1M | ||
| Q3 25 | $431.3M | $148.8M | ||
| Q2 25 | $416.7M | $-11.9M | ||
| Q1 25 | $406.5M | $18.9M | ||
| Q4 24 | $396.6M | $21.7M | ||
| Q3 24 | $389.9M | $11.2M | ||
| Q2 24 | $380.5M | $39.3M |
总资产FSBCRYTM
| Q1 26 | $5.0B | — | ||
| Q4 25 | $4.8B | $480.2M | ||
| Q3 25 | $4.6B | $506.9M | ||
| Q2 25 | $4.4B | $372.7M | ||
| Q1 25 | $4.2B | $386.7M | ||
| Q4 24 | $4.1B | $392.3M | ||
| Q3 24 | $3.9B | $363.6M | ||
| Q2 24 | $3.6B | $381.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-25.4M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FSBCRYTM
| Q1 26 | — | — | ||
| Q4 25 | $72.6M | $-25.4M | ||
| Q3 25 | $18.8M | $-26.6M | ||
| Q2 25 | $17.8M | $-23.3M | ||
| Q1 25 | $15.5M | $-40.4M | ||
| Q4 24 | $51.8M | $-18.8M | ||
| Q3 24 | $17.5M | $-25.2M | ||
| Q2 24 | $16.0M | $-29.1M |
自由现金流FSBCRYTM
| Q1 26 | — | — | ||
| Q4 25 | $71.4M | — | ||
| Q3 25 | $18.6M | — | ||
| Q2 25 | $17.5M | — | ||
| Q1 25 | $15.4M | — | ||
| Q4 24 | $51.2M | — | ||
| Q3 24 | $17.3M | — | ||
| Q2 24 | $15.8M | — |
自由现金流率FSBCRYTM
| Q1 26 | — | — | ||
| Q4 25 | 164.3% | — | ||
| Q3 25 | 45.0% | — | ||
| Q2 25 | 45.8% | — | ||
| Q1 25 | 43.5% | — | ||
| Q4 24 | 145.5% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 51.6% | — |
资本支出强度FSBCRYTM
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 1.8% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 0.7% | — |
现金转化率FSBCRYTM
| Q1 26 | — | — | ||
| Q4 25 | 4.12× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.18× | — | ||
| Q4 24 | 3.89× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FSBC
| Net Interest Income | $43.5M | 96% |
| Noninterest Income | $1.6M | 4% |
RYTM
暂无分部数据
